METASTATIC PROSTATE CANCER

This study is observing men with metastatic prostate cancer who are receiving a drug called lutetium-177 vipivotide tetraxetan, a type of targeted radiation therapy. Researchers will track how well the treatment works in everyday medical practice, including changes in PSA levels,…

This early-phase study tests a new drug, RO7656594, in people with advanced or metastatic prostate cancer that has spread. The main goals are to check the drug's safety, find the best dose, and see if it can help control the cancer. About 210 participants who have already tried o…

This study tests whether adding an immune-boosting treatment (Sipuleucel-T) to ongoing hormone therapy can better control metastatic prostate cancer that has started to progress. About 26 adults with asymptomatic or mildly symptomatic cancer will receive Sipuleucel-T either with …

This study tests whether combining a targeted radiation drug (177Lu-PSMA-617) with liver-directed therapy is safe for men with advanced prostate cancer that has spread to the liver. About 30 participants will receive both treatments to see how well they tolerate the combination a…

This study tests a new injectable radioactive drug, Actinium-225 rhPSMA-10.1, in men with advanced prostate cancer that has spread and no longer responds to standard treatments. The drug aims to find and destroy cancer cells with radiation. About 60 men will receive up to 6 doses…

This study tests a new treatment called AZD0754, which uses a patient's own immune cells (CAR T-cells) to fight metastatic prostate cancer. About 60 adults with castration-resistant prostate cancer will receive this therapy to see if it is safe and can shrink tumors or lower PSA …

This study tests an experimental drug called AZD0516, given alone or with other cancer medicines, for men with metastatic prostate cancer (cancer that has spread). The main goals are to check safety, find the best dose, and see if it can shrink tumors or lower PSA levels. About 1…

This study tests a drug called tarlatamab for men with a specific type of advanced prostate cancer (DLL3-positive) that has spread and either returned or stopped responding to treatment. The goal is to see if the drug can slow or stop cancer growth. About 32 participants will be …

This study compares standard systemic therapy alone versus standard therapy plus PET-directed local therapy in 464 veterans with prostate cancer that has returned in a few spots (oligorecurrence). The goal is to see if adding targeted local treatment can delay the cancer from bec…

This study tests whether adding dexamethasone or metronidazole (a gut bacteria-targeting antibiotic) can make abiraterone work again in men with metastatic prostate cancer whose disease has stopped responding to the drug. About 58 men will receive one of these combinations for up…

This study tests if adding a freezing procedure (cryoablation) and a low-dose chemotherapy pill (cyclophosphamide) to standard hormone therapy can better control metastatic prostate cancer. About 104 men with newly diagnosed, advanced prostate cancer will receive the combination.…

This study tests whether adding a second chemotherapy drug (platinum) to the usual treatment (docetaxel) can slow the growth of advanced prostate cancer that no longer responds to hormone therapy. It is for people whose tumors have certain DNA repair gene changes. About 236 parti…

This study tests whether a special PET scan using 18F-fluciclovine can better detect advanced prostate cancer that doesn't show up well on standard scans. It involves 30 people with metastatic prostate cancer that either has low PSMA levels or neuroendocrine features. Participant…

This study looks at whether two home-based exercise programs—using a stationary bike or walking—can help men with metastatic prostate cancer who are starting hormone therapy. Twenty-four participants will exercise at home for 12 weeks and complete fitness tests and questionnaires…

This study tests whether a 16-week supervised exercise program (circuit training with resistance, functional, and aerobic exercises) can improve frailty, muscle loss, and inflammation in men with metastatic prostate cancer who are on hormone therapy. The study will include 80 men…

This study collects blood samples from 1,000 men with prostate cancer to look for genetic differences that may explain why some cancers stop responding to hormone therapy. Participants give blood during clinic visits, and researchers analyze DNA and other genetic material. The go…

This study looks at whether taking endocrine therapy in the morning or evening makes a difference for people with metastatic breast or prostate cancer. About 50 participants will be randomly assigned to take their medication at one of these times. The main goal is to see if a lar…

This study looks at whether having a radiopharmacist review a patient's full medication list before they receive targeted radionuclide therapy (TRT) can improve safety. TRT is a type of radiation treatment that targets cancer cells while sparing healthy tissue. Researchers will c…

This study looks at ways to increase the number of men with metastatic prostate cancer who receive next-generation sequencing (NGS) testing. Researchers will test methods to overcome barriers for both doctors and patients. About 256 men newly seen at Johns Hopkins will take part.…